Autopsy report · NCT03439085
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
Cause of deathOther
“Project delays”
Life of this trial
- Registered 9 months before it started.
- Ran for about 3 years 10 months before it stopped.
- 41 participants enrolled.
- Results were posted on the registry 1 year 10 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Conditions
- Human Papillomavirus-16 Positive; Human Papillomavirus-18 Positive; Metastatic Malignant Neoplasm; Recurrent Anal Canal Carcinoma; Recurrent Cervical Carcinoma; Recurrent Malignant Neoplasm
- Interventions
- DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457; Durvalumab
- Participants
- 41
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.